Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 4
Submit an article Journal homepage
1,285
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey

Andrew DaviesOxford Outcomes Ltd OxfordUKCorrespondence[email protected]
,
Ameet BakhaiBarnet and Chase Farm NHS Trust, London, UK, and AMORE Health Ltd PinnerUK
,
Claude SchmittEli Lilly and Company Erl WoodUK
,
Annabel BarrettEli Lilly and Company Erl WoodUK
,
Peita Graham-ClarkeEli Lilly and Company Erl WoodUK
&
Mark SculpherUniversity of York, North Yorkshire, UK, and Oxford Outcomes Ltd OxfordUK
Pages 510-521 | Accepted 16 Jan 2013, Published online: 12 Feb 2013

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

William H. Olson, Yi-Wen Ma, Concetta Crivera, Jeff Schein, Patrick Lefebvre, François Laliberté, Katherine Dea, Guillaume Germain & Scott M. Lynch. (2015) Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. Journal of Medical Economics 18:12, pages 1074-1084.
Read now

Articles from other publishers (11)

Naser Yamani, Samuel Unzek, Muhammad Hasnain Mankani, Talal Almas, Adeena Musheer, Humera Qamar, Shausha Farooq, Waqas Shahnawaz, Kaneez Fatima, Vincent Figueredo & Farouk Mookadam. (2022) Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis. Annals of Medicine and Surgery 79, pages 103964.
Crossref
Mouaddh Abdulmalik Nagi, Pramitha Esha Nirmala Dewi, Montarat Thavorncharoensap & Sermsiri Sangroongruangsri. (2021) A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa. Applied Health Economics and Health Policy 20:3, pages 315-335.
Crossref
Alexandru-George Cotoban, Cristian Alexandru Udroiu & Dragos Vinereanu. (2021) Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. American Journal of Therapeutics 28:3, pages e271-e283.
Crossref
Laura Pirhonen, Hanna Gyllensten, Andreas Fors & Kristian Bolin. (2020) Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome. The European Journal of Health Economics 21:9, pages 1317-1327.
Crossref
Leopold Ndemnge Aminde, Noah Fongwen Takah, Belen Zapata-Diomedi & J. Lennert Veerman. (2018) Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Elizabeth R. Stevens, Daniel Farrell, Saahil A. Jumkhawala & Joseph A. Ladapo. (2018) Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. American Heart Journal 204, pages 17-33.
Crossref
Bastian Wein, Michael Coslovsky, Reza Jabbari, Søren Galatius, Matthias Pfisterer & Christoph Kaiser. (2017) Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. International Journal of Cardiology 248, pages 20-27.
Crossref
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Nigel Fleeman, Joanne McEntee, Yenal Dundar, Marty Richardson & Michael Fisher. (2015) Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment 19:29, pages 1-130.
Crossref
Fotini Gialama, Evangelia Miloni & Nikos Maniadakis. (2014) Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. PharmacoEconomics 32:11, pages 1063-1078.
Crossref
Radu M. Nanau, Faustine Delzor & Manuela G. Neuman. (2014) Efficacy and safety of prasugrel in acute coronary syndrome patients. Clinical Biochemistry 47:7-8, pages 516-528.
Crossref
Victor L. Serebruany & Seth D. Fortmann. (2017) Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics”. Thrombosis and Haemostasis 112:07, pages 4-9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.